Background: Depression and smoking contribute to the prognosis of autoimmune rheumatoid arthritis (RA). Advanced glycation end products (AGEs) are also detected in RA patients. This study correlates RA in patients with various levels of depression and a history of smoking through the detection of antibodies against AGEs of proteins. Methods: Sixty RA subjects were selected and divided into 4 groups based on their levels of depression and smoking habits. The division was as follows: group I consisted of RA patients classified as depressed (RA-D); group II consisted of RA patients with a history of smoking (RA-S); group III consisted of RA patients suffering from depression who were also smokers (RA-DS); and group IV consisted of patients with RA alone (RA-A), i.e., not depressed and non-smokers. In vitro human serum albumin (HSA) was modified by glucose, and the modifications were studied by biochemical and biophysical techniques. Glycated (G)-HSA was used as an antigen, and autoantibodies against G-HSA (G-HSA-Abs) were screened in serum samples of different groups of RA subjects. Oxidative stress levels in all patients and healthy individuals were analyzed by protein-bound carbonyl content estimations. Results: Significant biochemical and biophysical changes were detected in G-HSA when compared to native (N)-HSA. All patients and control subjects were screened for circulating G-HSA-Abs and N-HSA-Abs. From the cohort of different samples, serum autoantibodies from RA-DS showed a high recognition of G-HSA-Abs titres compared to RA-D or RA-S. RA-A exhibited the least binding of circulating G-HSA-Abs of all the groups. The oxidative stress marker, the carbonyl content also exhibited highest levels in RA-DS, followed by RA-D and RA-S. Band shift assay showed the highest titres of immunoglobulin G in the serum samples of RA-DS. Conclusions: Smoking and concomitant depression in RA subjects may lead to enhanced oxidative stress levels responsible for the gradual formation and/or exposing of cryptic epitopes on HSA that induce the production of G-HSA-Abs. Hence, we postulate that by reducing depression and corresponding oxidative stress, it may be possible to control or limit the severity of the precipitation of RA disease activity and improve prognosis.

1.
Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, Dixey J: Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007; 46: 350–357.
2.
Ferreira RA, Ferriani, VPL, Sopelete MC, Silva DAO, Mineo JR, Kiss MHB, Silva CHM: Immunoglobulin E-rheumatoid factor in juvenile rheumatoid arthritis. Rev Hosp Clin Fac Med S Paulo 2002; 57: 209–216.
3.
El-Miedany YM, El Rasheed AH: Is anxiety a more common disorder than depression in rheumatoid arthritis? Joint Bone Spine 2002; 69: 300–306.
4.
Gettings L: Psychological well-being in rheumatoid arthritis: a review of the literature. Musculoskeletal Care 2010; 8: 99–106.
5.
Dickens C, McGowan L, Clark-Carter D, Creed F: Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med 2002; 64: 52.
6.
Uguz F, Akman C, Kucuksarac S, Tufekci O: Antitumor necrosis factor therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin Neurosci 2009; 63: 50–55.
7.
Shmerling RH, Delbanco TL: How useful is the rheumatoid factor? An analysis of sensitivity, specificity and predictive value. Arch Intern Med 1992; 152: 2417–2420.
8.
Roland PN, Mignot SG, Bruns A, Hurtado M, Palazzo E, Hayem G, et al: Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arth Res Ther 2008; 10:R142.
9.
Cunha M, Ribeiro A, André S: Anxiety, depression and stress in patients with rheumatoid arthritis. Procedia Soc Behav Sci 2016; 217: 337–343.
10.
Schellekens GA, Visser H, de Jong BAW, van den Hoogen FH, Hazes JM, Breedeveld FC, van Venrooij WJ: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arth Rheum 2000; 43: 155–163.
11.
Despres N, Boire G, Lopez-longo FJ, Menard HA: The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis system. J Rheumatol 1994; 21: 1027–1033.
12.
De Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CGM, Bijl M, Posthumus MD: Advanced glycation end products are increased in rheumatoid arthritis patients with controlled disease. Arth Res and Ther 2011; 13:R205.
13.
Miyata T, Ishiguro N, Yasuda Y: Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis, and its relation with inflammatory markers. Biochem Biophys Res Commun 1998; 244: 49–49.
14.
Chen JR, Takahashi M, Suzuki M, Kushida S, Miyamoto S, Inoue T: Comparison of the concentrations of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1999; 38: 1275–1278.
15.
Tai AWH, Newkirk MM: An autoantibody targeting glycated IgG is associated with elevated serum immune complexes in rheumatoid arthritis. Clin Exp Immunol 2000; 120: 188–193.
16.
Fiehn C, Kratz F, Sass G, Müller-Ladner U, Neumann E: Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann Rheum Dis 2008; 67: 1188–1191.
17.
Newkirk MM, Goldbach-Mansky R, Lee J, Hoxworth J, McCoy A, Yarboro C, Klippel J, El-Gabalawy HS: Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res Ther 2003; 5: 82–90.
18.
Ligier S, Fortin PR, Newkrik MM: A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Rheumatol 1998; 37; 1307–1314.
19.
Peters T: Serum albumin. Adv Protein Chem 1985; 37: 161–245.
20.
Wunder A, Muller-Lander U, Stelzer EH, Funk J, Neumann E, Stehle G, et al: Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003; 170: 4793–4801.
21.
Fiehn C, Müller-Ladner U, Gay S, Krienke S, Freudenberg-Konrad J, Funk A, et al: Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatol 2004; 43: 1097–1105.
22.
Arnett FC, Edworthy SM, Block DA, McShane DJ, Fries JF, Cooper NS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–324.
23.
Kroenke K, Spitzer RL: The PHQ-9: a new depression and diagnostic severity measure. Psychiat Ann 2002; 32: 509–515.
24.
Bradford MM: A rapid and sensitive method for quantitation of micrograms quantity of protein utilizing the principle of protein dye binding. Anal Biochem 1976; 72: 248–254.
25.
Mashiba S, Uchida K, Okuda S, Tomita S: Measurement of glycated albumin by the nitroblue tetrazolium colorimetric method. Clin Chim Acta 1992; 212: 3–15.
26.
Ahmed N, Furth JA: A microassay for protein glycation based on the periodate method. Analyt Biochem 1991; 192: 109–111.
27.
Levine RL, Williams J, Stadtman ER, Shacter E: Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994; 233: 346–357.
28.
Liggins J, Furth JA: Role of protein-bound carbonyl groups in the formation of advanced glycation end products. Biochim Biophys Acta 1997; 1361: 123–130.
29.
Chen YH, Yang JT: A new approach to the calculation of secondary structures of globular proteins by optical rotatory dispersion and circular dichroism. Biochem Biophys Res Commun 1971; 44: 1285–1291.
30.
Khan MWA, Qadrie ZL, Khan WA: Antibodies against gluco-oxidatively modified human serum albumin detected in diabetes-associated complications. Int Arch Allergy Immunol 2010; 153: 207–214.
31.
Khan MWA, Banga K, Mashal SN, Khan WA: Detection of autoantibodies against reactive oxygen species modified glutamic acid decarboxylase-65 in type 1 diabetes associated complications. BMC Immunol 2011; 12: 19.
32.
Abdel-Nasser AM, Abd El-Azim S, Taal E, El-Badawy SA, Rasker JJ, Valkenburg HA: Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol 1998; 37: 391–397.
33.
Isik A, Koca SS, Ozturk A, Mermi O: Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 872–878.
34.
Margaretten M, Julian L, Katz P, Yelin E: Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumtol 2011; 6: 617–623.
35.
Katz PP, Yelin EH: Activity loss and the onset of depressive symptoms: do some activities matter more than others? Arthritis Rheum 2001; 44: 1194–1202.
36.
Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BWJH: Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology 2015; 51: 164–175.
37.
Khan MWA, Rasheed Z, Khan WA, Ali R: Biochemical, biophysical and thermodynamic analysis of in vitro glycated human serum albumin. Biochemistry 2007; 72: 146–152.
38.
Manavalan P, Johnson WC: Sensitivity of circular dichroism to protein tertiary structure class. Nature 1983; 305: 831–832.
39.
Stojanovich L, Marisavljevich D: Stress as a trigger of autoimmune disease. Autoimmun Rev 2008; 7: 209–213
40.
Heliovaara M, Aho K, Knekt P, Impivaara O, Reunanen A, Aromaa A: Coffee consumption, rheumatoid factor, and the risk of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 631–635.
41.
Hutchinson D, Moots R: Cigarette smoking and severity of rheumatoid arthritis. Rheumatol 2001; 40: 1426–1427.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.